Expression data from mesenchymal stromal cells derived from pediatric leukemia patients and healthy pediatric controls

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow microenvironment, where they are protected against chemotherapeutic agents. Mesenchymal stromal cells (MSCs) are key components of this supporting framework. The present study aimed to unravel whether MSCs derived from pediatric BCP-ALL patients (leukemic MSCs) differ from MSCs derived from healthy pediatric donors (control-MSCs). Therefore, we studied their gene expression profiles. Microarray analyses were performed of primary MSCs derived from bone marrow samples collected at initial diagnosis (n=35; day0-leukemic-MSCs), after induction and consolidation therapy when patients are in remission of their leukemia (n=29; day79 remission-MSCs), and at Relapse (n=6; Relapse-MSCs). These profiles were compared to the gene expression profiles of 16 control-MSCs.